nAChR antagonist 1 (compound B15) is an excellent α7 nAChR antagonist with an IC50 value of 3.3 μM. nAChR antagonist 1 can be used for researching schizophrenia, Alzheimer’s disease and inflammatory disorders[1].

Product information

Molecular Weight: 338.40

Formula: C19H22N4O2

Chemical Name: 3-[4-(2-methoxypyridin-4-yl)phenyl]-8-methyl-1-oxa-2, 4, 8-triazaspiro[4.5]dec-2-ene

Smiles: COC1=CC(=CC=N1)C1C=CC(=CC=1)C1NC2(CCN(C)CC2)ON=1

InChiKey: QDLDRBASXSECJO-UHFFFAOYSA-N

InChi: InChI=1S/C19H22N4O2/c1-23-11-8-19(9-12-23)21-18(22-25-19)15-5-3-14(4-6-15)16-7-10-20-17(13-16)24-2/h3-7,10,13H,8-9,11-12H2,1-2H3,(H,21,22)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: To be determined

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

References:

1. Zhang H, et al. Design, synthesis and biological activities of piperidine-spirooxadiazole derivatives as α7 nicotinic receptor antagonists. Eur J Med Chem. 2020;207:112774

Products are for research use only. Not for human use.